remain unclear. 15, 16 Interestingly, VSMCs internalize liverderived fetuin-A from the circulation and load it into exosomes where it acts as a potent inhibitor of calcification. Thus, both locally expressed and serum-derived proteins are involved in the prevention of exosome-mediated VSMC calcification. 5 Circulating vitamin K-dependent coagulation factors, including PT (prothrombin) and factors VII, IX, and X and proteins C and S, also harbor Gla residues which mediate Ca-dependent protein binding to negatively charged phospholipids, such as phosphatidylserine (PS). [17] [18] [19] [20] [21] Activation of coagulation in the vasculature has been linked to PS-exposing extracellular vesicles (EVs) shed by apoptotic macrophages, endothelial cells, erythrocytes, and VSMCs. 17, [22] [23] [24] In particular, the coagulation cascade is triggered by VSMC EVs bearing tissue factor (TF) that can activate factor VII with subsequent activation of the prothrombinase complex (consisting of factor Va, factor Xa, and calcium) to catalyze PT conversion to thrombin. 17, 22, [25] [26] [27] [28] Anticoagulation therapy with warfarin causes elevation of circulating levels of liver-derived uncarboxylated PT (PIVKA-II [protein induced by vitamin K absence or antagonism II]) and results in the inhibition of thrombogenesis. 29 Besides its effect on vitamin K-dependent coagulation proteins, warfarin increases circulating levels of undercarboxylated MGP and BGP and causes vascular calcification in rodent models and accelerates both valve and vascular calcification in man. [30] [31] [32] [33] However, despite the global use of anticoagulation therapies in clinical practice, the effects of warfarin on VSMC-mediated calcification remain elusive.
Here, we report that circulating vitamin K-dependent coagulation proteins, PT in particular, can bind to the surface of VSMC exosomes via PS and can also be loaded into exosomes by cellular internalization and recycling via the late endosome/multivesicular body (LE/MVB) compartment. We identify PT as a novel circulating calcification inhibitor that also acts to induce thrombin generation in a TF-and PS-dependent manner on the surface of exosomes. Thus, anticoagulation therapy with warfarin may enhance vascular calcification via impaired carboxylation of vitamin K-dependent coagulation factors delivered to VSMC exosomes, which play a dual role in calcification and coagulation.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Circulating Gla Proteins Are Abundant in VSMC Exosomes
We previously demonstrated the recycling of the circulating serum protein, fetuin-A by VSMC exosomes. 5 To determine whether other serum proteins are recycled in VSMC exosomes, we interrogated a proteomic data set of human VSMC-derived exosomes, 5 isolated under normal or calcifying conditions, for bovine proteins indicative of serum uptake. The most abundant bovine proteins in VSMC exosomes were albumin, fetuin-A, and fibronectin (Table 1) vitamin K-dependent coagulation proteins, including factors II (PT), IX and X, and anticoagulation proteins C and S, were also detected in VSMC-derived exosomes, and their loading was increased under calcifying conditions (Table 1 , Number of Assigned Spectra). We compared the primary structure of circulating vitamin K-dependent coagulation proteins and MGP. 7 The alignment of the Gla domain sequences revealed a similarity, of over 50% in the composition of the Gla domain between vitamin K-dependent coagulation proteins ( Figure IA and IB in the online-only Data Supplement). Prominently, there were 4 conserved Glu residues and 1 cysteine residue in all these proteins, suggesting that coagulation proteins may potentially modulate vascular calcification.
Gla Proteins Differentially Inhibit VSMC Calcification In Vitro
VSMCs were treated with physiological doses of several Glacontaining proteins to test their capacity to inhibit calcification in vitro ( Figure 1A ). MGP is a potent local inhibitor of calcification; however, circulating MGP has no inhibitory properties in vivo 34 and is only effective in vitro at doses above physiological levels. 35 As expected, MGP1-53 ( Figure IIA and IIC in the online-only Data Supplement), osteopontin, and osteocalcin had little effect on calcification when added exogenously to the media at circulating concentrations ( Figure 1A ). In contrast, PT, the most abundant circulating coagulation factor with physiological concentrations ≈1.4 μmol/L, was able to potently inhibit calcification in a manner similar to fetuin A ( Figure 1A) .
PT expression was not observed in VSMCs either by Western blotting or polymerase chain reaction ( Figure IIIA in the online-only Data Supplement). However, incubation of VSMCs with PT resulted in its accumulation in exosomes, apoptotic bodies, and whole cell lysates ( Figure 1B) , with exosomes also enriched with PT intermediate activation products, F1 and F1.2 ( Figure 1B ). In agreement with our proteomic data, calcifying conditions increased the levels of PT and F1 both in exosomes and in VSMCs ( Figure 1C ).
PT Inhibits Exosome-Induced Calcification and Reduces VSMC Apoptosis
To test further the effects of PT on vascular calcification, we treated VSMCs in elevated Ca/P conditions and assessed calcification by 45 Ca incorporation and alizarin red S staining ( Figure 2A and Figure IVA in the online-only Data Supplement). PT inhibited calcification in a dose-dependent manner at concentrations within the physiological range. The inhibitory effects of PT were more pronounced in Ca-induced rather than P-induced calcification ( Figure IVB and IVC in the online-only Data Supplement). Fetuin-A blocks calcification by binding to nascent Ca/P crystals preventing further growth and acting as a mineral chaperone. 36, 37 Fetuin-A and PT inhibited VSMC calcification in a synergistic manner, indicating that PT acts via different mechanisms ( Figure 2B ) and in agreement with this fetuin-A but not PT completely prevented Ca/P precipitation in vitro ( Figure 2C ).
To study the effects of PT on exosome-initiated calcification, exosomes were isolated from VSMCs treated in the absence or presence of PT, and their calcification potential was quantified ex vivo. 15 Exosomes isolated from Ca-/P-treated VSMCs displayed calcification ( Figure 2D ). Direct addition of PT to exosomes isolated from VSMCs incubated in Ca/P media significantly reduced exosome calcification ( Figure 2D ), suggesting that PT may inhibit calcification by binding to PS externalized on the exosome surface thus preventing nucleation site formation. However, inhibition of exosome calcification was also observed when VSMCs were treated with PT for 24 hours and then washed to remove PT from the media before exosome isolation 24 hours later, suggesting that PT is also loaded into exosomes via the LE/MVB pathway.
VSMC apoptosis also contributes to calcification, and treatment of VSMCs with calcifying media resulted in apoptosis of ≈20% to 25% of cells as assessed by TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labelling) staining and time-lapse microscopy ( Figure IVD and IVE in the online-only Data Supplement). Addition of PT significantly reduced VSMC apoptosis induced by elevated Ca/P, but had no effect on apoptosis induced by serum withdrawal (data not shown), suggesting PT can prevent mineral overload-induced apoptosis.
PT Is Recycled in VSMC Exosomes in a Ca-Dependent Manner
To test whether PT can directly bind to VSMC exosomes, we immobilized exosomes on latex beads, incubated with Alexa488-labeled PT and observed strong binding ( Figure 3A ). The interaction of PT with PS is mediated by the N-terminal F1 domain harboring Gla-residues, 20 and consistently, addition of annexin A5 or F1 blocked PT binding to exosomes ( Figure 3A ). We also observed reciprocal competition for interactions with exosomal PS between PT and annexin A5 ( Figure IIIB in the online-only Data Supplement).
Addition of alexa488-labeled PT to VSMCs resulted in endocytosis of full-length PT in a Ca-dependent manner ( Figure 3B ). To test whether PT endocytosis is mediated by high-affinity binding to a cellular receptor or fluid-phase uptake, 38 we studied endocytosis of alexa488-labeled PT in the presence of unlabeled PT. Notably, endocytosis of alexa488-labeled PT was inhibited by 5-fold molar excess of unlabeled PT, indicating that uptake is mediated by highaffinity binding of PT to the cell surface potentially via Gla/ PS binding ( Figure 3C ). Colocalization with EEA1 (early endosome antigen 1) and CD63 showed that PT is endocytosed by VSMCs and delivered to early endosomal and LE/ MVB compartments ( Figure 3D ). Immunocytochemistry also confirmed that PT-Alexa488 uptake was further stimulated by elevated Ca and inhibited by unlabeled PT ( Figure 3D ). To distinguish PT that binds to exosomes in the cell media, and PT that is endocytosed and recycled in exosomes via LE/ MVB, we incubated VSMCs with PT for 16 hours (pulse) and then washed cells with acidic buffer (pH 2.5) to remove all cell surface bound PT and continued incubation in media without PT (chase). Exosomes isolated from VSMCs incubated in the presence of PT in the media were enriched with full-length protein and fragments, F1.2 and F1 ( Figure 3E ). In contrast, exosomes obtained after the chase treatment contained full-length PT and its intermediate activation product with molecular weight ≈34 kDa, most likely Pre2 (prethrombin-2), an inactive α-thrombin precursor consisting of the catalytic domain. (Figure 3E and Figure IC in the online-only Data Supplement). Thus, PT is loaded on, and in, exosomes by direct surface binding and cellular endocytosis.
Gla Domain but not Proteolytic Activity Is Required for VSMC Calcification Inhibition by PT
To identify the domain of PT responsible for blocking calcification, we tested different PT forms ( Figure 4A ). F1 that contains 10 Gla residues was the most potent inhibitor, even more effective than full-length PT. F2, which does not contain a Gla domain, and uncarboxylated (Glu)-PT were also able to inhibit calcification although to a much lesser extent, indicating that several domains contribute to PT effects on calcification. In contrast, thrombin had no effect on VSMC calcification ( Figure 4A ). To confirm that catalytic activity is not required for the PT inhibitory effect, we showed that addition of the thrombin inhibitor hirudin did not abrogate PT inhibitory effects on VSMC calcification ( Figure 4B ). Finally, to investigate whether other Gla-containing coagulation proteins identified in exosomes may also affect VSMC calcification, we used a Gla peptide representing the N-terminal region of protein S containing 11 Gla residues, which forms a stable conformation because of its intramodular disulfide loop ( Figure IIB and IIC in the online-only Data Supplement). Addition of this Gla peptide completely abrogated VSMC calcification ( Figure 4B ), confirming the utility of Gla residues in inhibiting calcification.
PT Accumulates at Sites of Calcification In Vivo and Is Reduced in Patients With Vascular Calcification
To confirm a relationship between calcification and PT, we analyzed the distribution of PT in the calcified vasculature using an F1-specific antibody. Immunohistochemistry showed that low levels of PT were deposited in the healthy vessel wall, whereas in calcified vessels PT was significantly present in both intimal and medial layers ( Figure 4C ). Moreover, we observed overlap between the distribution of PT and fetuin-A, suggesting that PT is deposited in the vessel wall most likely via exosomes in a manner similar to fetuin-A.
5,36
Fetuin-A levels are reduced in patients with vascular calcification; thus, we tested whether there is also a correlation between vascular calcification and PT concentration. Vascular calcification of the iliac arteries was assessed by plain radiograph of the pelvis (Table 2) . Patients with vascular calcification had lower levels of PT (P<0.01) when compared with patients without calcification. Univariate logistic regression confirmed this finding (P=0.012; hazard ratio, 0.971; 95% confidence interval, 0.948-0.993) and after adjustment for age, sex, and diabetes mellitus the finding remained significant (P=0.004; hazard ratio, 0.905; 95% confidence interval, 0.845-0.969). Addition of fetuin-A levels to the multivariable model did not change the results (data not shown).
VSMC Exosomes Display TF and PSDependent Procoagulant Activity
The accumulation of PT activation products, F1 and F1.2 in exosomes ( Figure 1B) , suggested that exosomes may play a role in thrombin activation ( Figure IC in the online-only Data Supplement), so we tested whether VSMC exosomes contain TF and found it was enriched in exosomes but not apoptotic bodies ( Figure 5A ). The addition of VSMC exosomes to plasma potently stimulated thrombogenesis, which was abrogated in the presence of annexin A5 (Figure 5B ), confirming thrombogenic activity is via PS exposure. Once PT is activated, F1 and F1.2 bound to exosomes may prevent further activation of PT by blocking PS sites. Indeed, exosomes isolated from VSMCs preincubated with PT demonstrated reduced thrombogenic activity ( Figure 5C ).
Notably, no thrombin activation was observed in PT-deficient plasma on addition of exosomes with bound PT (data not shown). PT binding to exosomes may prevent prothrombinase formation by blocking PS, so we tested whether exosome-associated PT can be activated by a preactivated prothrombinase complex. First, we incubated PT and factors Va/Xa with exosomes isolated from VSMCs incubated in the absence of PT and analyzed the supernatant and exosomeassociated products by Western blotting using antibodies specific for either F1 or catalytic domain ( Figure 5D ). No PT was detected in the exosomes isolated from VSMCs incubated in PT-free conditions ( Figure 5D, lane 1) . On addition of PT, we observed soluble and exosome-associated full-length PT ( Figure 5D, lane 2) . Addition of activated prothrombinase (Va/ Xa) along with PT resulted in the release of thrombin heavy chain (B chain) with molecular weight ≈31 kDa in the supernatant phase ( Figure 5D, lane 3) . We also observed B chain and activation product F1 associated with exosomes ( Figure 5D,  lane 3) . Next, we analyzed exosomes isolated from VSMCs treated in the presence of PT. Using anti-F1 antibodies, we detected PT and PT intermediate activation products, F1 and F1.2 associated with exosomes ( Figure 5D, lane 4) . Using an anticatalytic domain antibody, we detected PT and an intermediate activation product with molecular weight ≈34 kDa ( Figure 5C , line 4), again most likely Pre2 compared with the position of B chain ( Figure 5D, lane 3) . Addition of prothrombinase had no effect on exosome-associated PT and PT activation products ( Figure 5D , line 5), indicating that there is a pool of exosome-bound PT and PT intermediate activation products not available to prothrombinase. Thus, VSMC exosomes are thrombogenic; however, accumulation of PT and PT intermediate activation products reduces their prothrombogenic properties in a negative feedback loop.
Altogether these data show that VSMC exosomes activate coagulation in a TF-and PS-dependent manner and accumulation of PT and PT activation products diminishes both PS-mediated procalcific and procoagulant exosomal activities in a negative feedback manner.
Discussion
PT Is Loaded on VSMC Exosomes and Protects Against Calcification in a Gla-Dependent Manner
Vitamin K antagonist treatment aimed at the prevention of thromboembolic complication causes accelerated vascular calcification in both animal models and patients, 32, 33 and this effect is thought to be associated with the accumulation of uncarboxylated endogenously expressed Gla proteins, such as MGP and GRP. 7, 8, 10, 30 In the present study, we show for the first time that the Gla residues in circulating coagulation factors, PT in particular, also contribute to inhibition of vascular calcification. As opposed to fetuin-A, a circulating calcification inhibitor that acts by directly binding to nascent growing calcium phosphate crystals to limit growth, 5, 37 PT inhibits exosome-mediated calcification via a PS/Gla interaction, thus disrupting nucleation site formation. Pulse-chase experiments indicated that there are 2 mechanisms of PT loading into exosomes, direct binding to the exosomal membrane and calcium-dependent endocytosis and secretion via the LE/MVB/ exosome pathway. The contribution of the latter pathway of PT loading into exosomes on calcification is currently unclear. This PT pool may be loaded inside exosomes via unknown mechanisms described previously for fetuin-A 5, 39 where it can shield luminal PS, thus enhancing the overall protective effects against calcification. Interestingly, PT endocytosis and exosomal loading were stimulated by calcium, which is required for the PS/Gla interaction, 40 and elevated calcium conditions have been observed in atherosclerotic plaques 41 and in patients with chronic kidney disease, suggesting that the internal loading pathway may be important under conditions of mineral imbalance. Accumulating evidence demonstrates the toxicity of crystalline Ca/P particles; thus, inhibition of crystal nucleation by PS/Gla interactions could also limit VSMC apoptosis. 42, 43 Interestingly, fragment F2 also displayed a modest protective effect, indicating that the F2 kringle 2 domain could contribute to the regulation of VSMC viability in calcifying conditions by modulating cell signaling, but this hypothesis is yet to be tested.
Importantly, extensive calcification of elastic fibers is commonly observed in patients with pseudoxanthoma elasticum harboring mutations in γ-glutamyl carboxylase, which causes multiple coagulation factor deficiency, 44 providing further evidence that Gla-containing coagulation factors may regulate vascular calcification in vivo. PTs role in calcification is also supported independently by previous reports showing its presence in association with calcified kidney stones. 45 In this study, we also detected PT in close association with calcified regions in human arteries where its distribution overlapped with fetuin-A deposits and the reduction of circulating PT levels negatively correlated with vascular calcification. These data mirror previous clinical data with fetuin-A showing reduced levels in dialysis patients who exhibit enhanced vascular calcification and mineral imbalance. 46 Interestingly, as opposed to MGP clinical data, the appearance of minute levels of undercarboxylated PT in the circulation (>2 ng/mL, which corresponds to ≈0.00003 µmol/L) is not associated with vascular calcification 47 as long as the total circulating PT levels remain high (≈1.4 µmol/L). Although the mechanisms of fetuin-A and PT loss in the circulation in dialysis patients are yet to be investigated, it is tempting to speculate that the major cause is the formation of fetuin-mineral complexes consisting of Ca/P and fetuin-A initially identified in the serum of rats treated with bisphosphonates. 48 Formation of complexes between fetuin-A and nascent mineral nuclei into primary calciprotein complexes is thought to inhibit further mineral growth and may facilitate clearance from the blood, 48 and these complexes have been recently associated with coronary artery calcification scores and aortic pulse wave velocity in patients with chronic kidney disease. 49, 50 However, the exact composition of these complexes remains elusive, and PT and fetuin-A-loaded exosomes may contribute by providing the membrane surface to form the fetuin-A-mineral complex core at early phases of calciprotein complex formation. In vivo, these complexes are yet to be tested for the presence of PT and exosomal markers, such as CD63 or Tsg101, and it would also be interesting to test how warfarin treatment affects the composition of these complexes.
VSMC Exosomes Are Thrombogenic
Recent studies suggest that thrombogenic activity in the atherosclerotic plaque is associated with EVs shed by apoptotic cells, especially VSMCs. 17, 22, 25, 26 Although VSMC EV thrombogenic activity exceeds the potency of platelet-derived EVs, most likely because of the presence of TF and PS, the mechanisms of thrombogenic EV secretion by VSMCs remained unknown. 22 TF has recently been shown to be secreted in exosomes in various cell types and was detected in VSMCs in cytoplasmic MVB-like structures and in VSMC culture media in small particles of an unknown nature. 24, 51, 52 Here, we report that apart from triggering calcification, PS externalized on VSMC exosomes acts as a catalytic surface for thrombogenesis. Interestingly, activation of PT on apoptotic cells or synthetic PS/PC vesicles occurs via the initial cleavage of PT at R320 yielding meizothrombin, a potent activator of anticoagulant pathways. 53, 54 In contrast, we detected Pre2 and F1.2 on VSMC exosomes, indicating that activation of PT on VSMC exosomes occurs by the PT cleavage at R271 generating catalytically inactive Pre2 and F1.2 and Pre2 can be instantly cleaved at R320 generating procoagulant α-thrombin. 55 This specificity may be defined by specific membrane proteins, such as integrins, as reported earlier for platelets. 56 Unexpectedly, we observed a pool of exosomeassociated PT and Pre2 that was not available for activation by factor Xa, and these exosomes displayed reduced thrombogenic activity. There are 2 possible explanations for this pool of PT that cannot be activated. First, PT may be loaded inside the exosomal lumen as discussed above. Second, activation of PT by factor Xa, by cleavage of the R320 bond in particular, requires membrane binding of factor Xa, suggesting sterical hindrance may prevent activation of PT and Pre2. 28 In conclusion, PT is a novel circulating vascular calcification inhibitor acting via Gla/PS binding to exosomes. Binding of PT to exosomes also activates coagulation pathways, whereas gradual loading of exosomes with PT and PT activation products reduces both procalcification and procoagulant activities by Gla/PS interactions. Hence, vascular protection in patients at high risk for vascular calcification may be achieved by using direct oral anticoagulants instead of warfarin or by supplementation with small Gla peptides, for example, Gla peptide derivative from protein S. Modulation of exosome biogenesis pathways, such as SMPD3 that is activated in vascular pathologies, 57, 58 may also provide alternative therapeutic approaches to reduce plaque thrombogenicity causing late stage thrombotic events in patients after myocardial infarction or coronary artery stenting.
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